Christopher G Parsons

List of Publications by Year in Descending Order

75 papers	4,224 citations	32 h-index	64 g-index
76 ext. papers	4,508 ext. citations	5.3 avg, IF	5.46 L-index

#	Paper	IF	Citations
75	Inhalational Anesthetics Do Not Deteriorate Amyloid-β-Derived Pathophysiology in Alzheimer's Disease: Investigations on the Molecular, Neuronal, and Behavioral Level. *Journal of Alzheimer's Disease*, **2021**, 84, 1193-1218	4.3	
74	The Aβ aggregation modulator MRZ-99030 prevents and even reverses synaptotoxic effects of Aβ on LTP even following serial dilution to a 500:1 stoichiometric excess of Aβ suggesting a beneficial prion-like seeding mechanism. *Neuropharmacology*, **2020**, 179, 108267	5.5	4
73	The anaesthetic xenon partially restores an amyloid beta-induced impairment in murine hippocampal synaptic plasticity. *Neuropharmacology*, **2019**, 151, 21-32	5.5	4
72	CNS repurposing - Potential new uses for old drugs: Examples of screens for Alzheimer's disease, Parkinson's disease and spasticity. *Neuropharmacology*, **2019**, 147, 4-10	5.5	11
71	The NMDA receptor antagonist Radiprodil reverses the synaptotoxic effects of different amyloid-beta (Aβ) species on long-term potentiation (LTP). *Neuropharmacology*, **2018**, 140, 184-192	5.5	14
70	Involvement of GluN2B subunit containing N-methyl-d-aspartate (NMDA) receptors in mediating the acute and chronic synaptotoxic effects of oligomeric amyloid-beta (Aβ) in murine models of Alzheimer's disease (AD). *Neuropharmacology*, **2017**, 123, 100-115	5.5	17
69	Preclinical to phase II amyloid beta (A) peptide modulators under investigation for Alzheimer's disease. *Expert Opinion on Investigational Drugs*, **2017**, 26, 579-592	5.9	21
68	Effects of sarizotan in animal models of ADHD: challenging pharmacokinetic-pharmacodynamic relationships. *Journal of Neural Transmission*, **2015**, 122, 1221-38	4.3	3
67	Brain concentrations of mGluR5 negative allosteric modulator MTEP in relation to receptor occupancy--Comparison to MPEP. *Pharmacological Reports*, **2015**, 67, 624-30	3.9	7
66	MRZ-99030 - A novel modulator of Aβ aggregation: II - Reversal of Aβ oligomer-induced deficits in long-term potentiation (LTP) and cognitive performance in rats and mice. *Neuropharmacology*, **2015**, 92, 170-82	5.5	17
65	MRZ-99030 - A novel modulator of Aβ aggregation: I - Mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer's disease, glaucoma and age-related macular degeneration (AMD). *Neuropharmacology*, **2015**, 92, 158-69	5.5	22
64	Patch clamp combined with voltage/concentration clamp to determine the kinetics and voltage dependency of N-methyl-D-aspartate (NMDA) receptor open channel blockers. *Methods in Molecular Biology*, **2014**, 1183, 43-63	1.4	
63	Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease. *Neurotoxicity Research*, **2013**, 24, 358-69	4.3	184
62	Preparation and testing of homocubyl amines as therapeutic NMDA receptor antagonists. *Medicinal Chemistry Research*, **2013**, 22, 360-366	2.2	22
61	Lipid raft integrity affects GABAA receptor, but not NMDA receptor modulation by psychopharmacological compounds. *International Journal of Neuropsychopharmacology*, **2013**, 16, 1361-71	5.8	23
60	GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats. *ACS Chemical Neuroscience*, **2013**, 4, 808-16	5.7	12
59	Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections. *British Journal of Pharmacology*, **2012**, 167, 324-52	8.6	310

58	Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease. *Expert Review of Neurotherapeutics*, **2012**, 12, 1351-65	4.3	32
57	Assessment of the effects of NS11394 and L-838417, α2/3 subunit-selective GABA(A) [corrected] receptor-positive allosteric modulators, in tests for pain, anxiety, memory and motor function. *Behavioural Pharmacology*, **2012**, 23, 790-801	2.4	14
56	Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of β-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices. *Neuropharmacology*, **2011**, 60, 982-90	5.5	122
55	Synthesis of a series of β-amino alcohols comprising an N-methyl isoindoline moiety and their evaluation as NMDA receptor antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 5795-9	2.9	15
54	Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia. *Journal of Neural Transmission*, **2011**, 118, 1703-16	4.3	23
53	Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. *American Journal of Pathology*, **2010**, 176, 870-80	5.8	160
52	In vivo evidence for functional NMDA receptor blockade by memantine in rat hippocampal neurons. *Journal of Neural Transmission*, **2010**, 117, 1189-94	4.3	8
51	Synergism of virtual screening and medicinal chemistry: identification and optimization of allosteric antagonists of metabotropic glutamate receptor 1. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 5708-15	3.4	23
50	Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-D-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/GluN2A) receptors. *Neuropharmacology*, **2009**, 56, 866-75	5.5	58
49	Memantine does not show intracellular block of the NMDA receptor channel. *European Journal of Pharmacology*, **2008**, 587, 99-103	5.3	13
48	Positive and negative modulation of group I metabotropic glutamate receptors. *Journal of Medicinal Chemistry*, **2008**, 51, 634-47	8.3	48
47	Blocking kinetics of memantine on NR1a/2A receptors recorded in inside-out and outside-out patches from Xenopus oocytes. *Journal of Neural Transmission*, **2008**, 115, 1367-73	4.3	4
46	Memantine as an example of a fast, voltage-dependent, open channel N-methyl-D-aspartate receptor blocker. *Methods in Molecular Biology*, **2007**, 403, 15-36	1.4	31
45	Searching for drug scaffolds with 3D pharmacophores and neural network ensembles. *Angewandte Chemie - International Edition*, **2007**, 46, 5336-9	16.4	18
44	Virtual screening for selective allosteric mGluR1 antagonists and structure-activity relationship investigations for coumarine derivatives. *ChemMedChem*, **2007**, 2, 1763-73	3.7	31
43	Neuroprotective activity of selective mGlu1 and mGlu5 antagonists in vitro and in vivo. *European Journal of Pharmacology*, **2007**, 554, 18-29	5.3	35
42	Inhibition of the alpha9alpha10 nicotinic cholinergic receptor by neramexane, an open channel blocker of N-methyl-D-aspartate receptors. *European Journal of Pharmacology*, **2007**, 566, 11-9	5.3	26
41	Agonist concentration dependency of blocking kinetics but not equilibrium block of N-methyl-D-aspartate receptors by memantine. *Neuropharmacology*, **2007**, 53, 415-20	5.5	19

40	Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. *Neuropharmacology*, **2007**, 53, 699-723	5.5	509
39	Predicting compound selectivity by self-organizing maps: cross-activities of metabotropic glutamate receptor antagonists. *ChemMedChem*, **2006**, 1, 1066-8	3.7	51
38	3-Nitropropionic acid toxicity in hippocampus: protection through N-methyl-D-aspartate receptor antagonism. *Hippocampus*, **2006**, 16, 834-42	3.5	30
37	mGlu1 and mGlu5 receptor antagonists lack anticonvulsant efficacy in rodent models of difficult-to-treat partial epilepsy. *Neuropharmacology*, **2006**, 50, 1006-15	5.5	26
36	The antiallodynic effect of NMDA antagonists in neuropathic pain outlasts the duration of the in vivo NMDA antagonism. *Neuropharmacology*, **2006**, 51, 12-7	5.5	37
35	Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. *Behavioural Pharmacology*, **2006**, 17, 411-24	2.4	104
34	Peripherally acting NMDA receptor/glycineB site receptor antagonists inhibit morphine tolerance. *Neuropharmacology*, **2005**, 48, 360-71	5.5	21
33	N-methyl-D-aspartate receptors mediate endogenous opioid release in enteric neurons after abdominal surgery. *Gastroenterology*, **2005**, 128, 2009-19	13.3	24
32	New allosteric modulators of metabotropic glutamate receptor 5 (mGluR5) found by ligand-based virtual screening. *ChemBioChem*, **2005**, 6, 620-5	3.8	21
31	Effects of low-affinity NMDA receptor channel blockers in two rat models of chronic pain. *Neuropharmacology*, **2004**, 47, 175-175	5.5	
30	Chronic memantine does not block 3-nitropropionic acid-delayed ischaemic tolerance in rat hippocampal slices ex vivo. *Neurotoxicity Research*, **2004**, 5, 617-22	4.3	5
29	Effects of low-affinity NMDA receptor channel blockers in two rat models of chronic pain. *Neuropharmacology*, **2004**, 47, 175-83	5.5	32
28	Are neuronal nicotinic receptors a target for antiepileptic drug development? Studies in different seizure models in mice and rats. *European Journal of Pharmacology*, **2003**, 466, 99-111	5.3	33
27	The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. *International Journal of Geriatric Psychiatry*, **2003**, 18, S23-32	3.9	266
26	Expression of polyglutamine-expanded huntingtin induces tyrosine phosphorylation of N-methyl-D-aspartate receptors. *Journal of Biological Chemistry*, **2003**, 278, 33364-9	5.4	67
25	Neuroprotective potential of ionotropic glutamate receptor antagonists. *Neurotoxicity Research*, **2002**, 4, 119-26	4.3	40
24	NMDA receptors as targets for drug action in neuropathic pain. *European Journal of Pharmacology*, **2001**, 429, 71-8	5.3	178
23	Mrz 2/579, a fast kinetic NMDA channel blocker, reduces the development of morphine tolerance in awake rats. *Pain*, **2001**, 91, 201-207	8	17

22	Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease--a unified glutamatergic hypothesis on the mechanism of action. *Neurotoxicity Research*, **2000**, 2, 85-97	4.3	170
21	Differential effects of NMDA-receptor antagonists on long-term potentiation and hypoxic/hypoglycaemic excitotoxicity in hippocampal slices. *Neuropharmacology*, **2000**, 39, 631-42	5.5	24
20	Expression of early hippocampal CA1 LTP does not lead to changes in AMPA-EPSC kinetics or sensitivity to cyclothiazide. *Pflugers Archiv European Journal of Physiology*, **1999**, 437, 191-6	4.6	13
19	Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization. *Neuropharmacology*, **1999**, 38, 85-108	5.5	122
18	Memantine restores long term potentiation impaired by tonic N-methyl-D-aspartate (NMDA) receptor activation following reduction of Mg2+ in hippocampal slices. *Neuropharmacology*, **1999**, 38, 1253-9	5.5	98
17	Electrophysiological study, biodistribution in mice, and preliminary PET evaluation in a rhesus monkey of 1-amino-3-[18F]fluoromethyl-5-methyl-adamantane (18F-MEM): a potential radioligand for mapping the NMDA-receptor complex. *Nuclear Medicine and Biology*, **1998**, 25, 323-30	2.1	38
16	Budipine is a low affinity, N-methyl-D-aspartate receptor antagonist: patch clamp studies in cultured striatal, hippocampal, cortical and superior colliculus neurones. *Neuropharmacology*, **1998**, 37, 719-27	5.5	19
15	Interactions of GYKI 52466 and NBQX with cyclothiazide at AMPA receptors: experiments with outside-out patches and EPSCs in hippocampal neurones. *Neuropharmacology*, **1998**, 37, 1299-320	5.5	26
14	Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices. *British Journal of Pharmacology*, **1996**, 117, 689-97	8.6	108
13	Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells. *British Journal of Pharmacology*, **1996**, 119, 195-204	8.6	80
12	Interactions of 2,3-benzodiazepines and cyclothiazide at AMPA receptors: patch clamp recordings in cultured neurones and area CA1 in hippocampal slices. *British Journal of Pharmacology*, **1996**, 117, 1209-21	8.6	43
11	Zinc changes AMPA receptor properties: results of binding studies and patch clamp recordings. *Neuropharmacology*, **1996**, 35, 503-9	5.5	40
10	Learning deficits induced by chronic intraventricular infusion of quinolinic acid--protection by MK-801 and memantine. *European Journal of Pharmacology*, **1996**, 296, 1-8	5.3	71
9	Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. *European Journal of Neuroscience*, **1996**, 8, 565-71	3.5	120
8	Memantine selectively depresses NMDA receptor-mediated responses of ratspinal neurones in vivo. *Neuroscience Letters*, **1994**, 165, 37-40	3.3	25
7	Whole cell and single channel analysis of the kinetics of glycine-sensitive N-methyl-D-aspartate receptor desensitization. *British Journal of Pharmacology*, **1993**, 109, 213-21	8.6	32
6	Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). *Neuropharmacology*, **1993**, 32, 1337-50	5.5	243
5	Effects of intravenous mu and kappa opioid receptor agonists on sensory responses of convergent neurones in the dorsal horn of spinalized rats. *British Journal of Pharmacology*, **1991**, 103, 1230-6	8.6	14

4	Peripheral opioid receptors mediating antinociception in inflammation. Activation by endogenous opioids and role of the pituitary-adrenal axis. *Pain*, **1990**, 41, 81-93	8	53
3	Spinal antinociceptive actions of mu- and kappa-opioids: the importance of stimulus intensity in determining selectivity between reflexes to different modalities of noxious stimulus. *British Journal of Pharmacology*, **1989**, 98, 523-32	8.6	39
2	Spinal antinociceptive actions and naloxone reversibility of intravenous mu- and kappa-opioids in spinalized rats: potency mismatch with values reported for spinal administration. *British Journal of Pharmacology*, **1989**, 98, 533-43	8.6	24
1	On the selectivity of intravenous mu- and kappa-opioids between nociceptive and non-nociceptive reflexes in the spinalized rat. *British Journal of Pharmacology*, **1989**, 98, 544-51	8.6	9